Scilex Holding announced that a recent market research study among rheumatologists revealed a high degree of interest in Gloperba as a liquid colchicine formulation designed for precision dosing. Specifically, clinicians using colchicine for prophylaxis of gout flares in adults indicated a strong likelihood to use Gloperba instead of tablets/capsules in certain at-risk patient populations who have a clinical need for lowered precision dosing to mitigate the risk of colchicine toxicity. Notably, the American College of Rheumatology guidelines also reflect this need. Scilex is currently in discussions with the U.S. Food and Drug Administration regarding the dosing recommendations for these patient populations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SCLX:
- Scilex Holding Company announces major pharmacy initiative with the national leading pharmacy chain to stock ELYXYB® in most of their stores throughout the U.S.
- Scilex says national pharmacy chain to stock ELYXYB in most U.S. stores
- Scilex announces expanded access to ELYXYB
- Scilex’s ZTlido will be added as preferred agent to Medicaid PDL in two states
- Scilex Holding Company announces that ZTlido® (lidocaine topical system) will be added as a preferred agent to the Medicaid Preferred Drug List (PDL) in two new states: one Midwestern and one Southern State